Yu. A. Fominykh

Yu. A. Fominykh

Auto-generated profile, based on publicly available information

Yu. A. Fominykh

Saint Petersburg State Pediatric Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2025 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
ODOxana M. Drapkina
Oxana M. Drapkina
MMM. V. Maevskaya
M. V. Maevskaya
KRK. L. Raikhelson
K. L. Raikhelson
SOSergey Okovityi
Sergey Okovityi
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.

23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
NBNataia V Baryshnikova
Nataia V Baryshnikova
YUYu.P. Uspensky
Yu.P. Uspensky
YFYu.A. Fominykh
Yu.A. Fominykh
EKE.Yu. Kalinina
E.Yu. Kalinina
YKYu.S. Krylova
Yu.S. Krylova
ВАВера A. Апрятина
Вера A. Апрятина
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить влияние стимулятора репарации альфа-глутамил-триптофана на морфологические характеристики слизистой оболочки желудка и экспрессию CXCL-12 и CDX-2 при хроническом атрофическом гастрите, ассоциированном с Helicobacter pylori. МАТЕРИАЛ И МЕТОДЫ Проанализированы образцы биопсийного материала 116 пациентов с верифицированным диагнозом хронического атрофического гастрита, ассоциированного с Helicobacter pylori, в рамках многоцентрового двойного слепого рандомизированного плацебо-контролируемого исследования. При морфологическом исследовании оценивали параметры, характеризующие процесс атрофии: количество желез на 1 мм2 слизистой оболочки желудка, глубину желез слизистой оболочки желудка, количество обкладочных клеток на 100 эпителиальных клеток слизистой оболочки желудка, наличие признаков кишечной метаплазии. Для постановки иммуногистохимических реакций для верификации экспрессии CXCL-12 и CDX-2 использовали первичные антитела Anti-CXCL-12 (MA5-23759) и Anti-CDX-2 (EP25). Морфологический анализ и иммуногистохимическое исследование биоптатов проводили до начала терапии и после окончания приема исследуемого препарата/плацебо. РЕЗУЛЬТАТЫ На фоне терапии у пациентов, принимавших исследуемый препарат, выявлено статистически значимое увеличение количества желез на 1 мм2 слизистой оболочки желудка при сравнении с исходными показателями скрининга на 26,1% (p=0,028) и с группой плацебо (p=0,026), определена тенденция к уменьшению кишечной метаплазии. Отмечено статистически значимое увеличение относительной площади экспрессии CXCL-12 у пациентов, принимавших плацебо, при сравнении с параметрами исходных данных (p=0,045) и отсутствие статистически значимых изменений в основной группе. Выявлено статистически значимое увеличение относительной площади экспрессии CDX-2 в группе принимавших альфа-глутамил-триптофан в сравнении с исходными данными (p=0,015), статистически значимой динамики данного показателя в группе плацебо не обнаружено. ЗАКЛЮЧЕНИЕ Установлено статистически значимое в сравнении с контролем исходного состояния и плацебо положительное влияние исследуемого препарата на регенераторные механизмы, приводящие к стабилизации и/или улучшению гистологической картины слизистой оболочки желудка. Результаты иммуногистохимического исследования по повышению экспрессии CDX-2 на фоне приема исследуемого препарата также можно расценить как показатель улучшения репаративных процессов.

31 August 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
YUYu. P. Uspenskiy
Yu. P. Uspenskiy
SISergei Vitalyevich Ivanov
Sergei Vitalyevich Ivanov
YFYu. A. Fominikh
Yu. A. Fominikh
MGMichael Galagudza
Michael Galagudza
ЮУЮ. П. Успенский
Ю. П. Успенский
ЮФЮ. А. Фоминых
Ю. А. Фоминых
Background. Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) are serious problem in modern gastroenterology, as these diseases affect the working population, have a progressive chronic course, a high risk of disabling complications and require significant costs for the drug management.Aim. We wanted to assess the inflammatory bowel diseases structure and features of the use of basic drugs in outpatient and inpatient treatment in St. Petersburg, Russia.Materials and methods. A cross-sectional study was performed. Data about drug therapy, disease features and demographic from 42 outpatient institutions and from 6 city hospitals for the period 2018–2020 in St. Petersburg was collected. The analysis included data from 617 patients with ulcerative colitis and 455 patients with Crohn’s disease.Results. The median age of patients with ulcerative colitis was 44 years, which was statistically significant more than with Crohn’s disease (39 years). In ulcerative colitis, the left-sided localization of colon lesions (56%) prevailed over total colitis (23%) and proctitis (21%) In Crohn’s disease, the prevalence of ilecocolitis (36%) was approximately equal to the prevalence of colitis (35%), the frequency of terminal ileitis was significantly less (26%), other variants of gastrointestinal lesions were found in 3% cases. In Crohn’s disease compared to ulcerative colitis, the proportion of patients with mild disease was similar (36.6% and 38.2% respectively), but in in Crohn’s disease the frequency of severe disease there was more than three times compared to ulcerative colitis. There has been a significantly higher incidence of surgery in the past for Crohn’s disease compared to ulcerative colitis (14.8% and 2.6%, respectively). The vast majority of patients (more than 80%) received therapy with oral 5-aminosalycilic acid drugs. Topical formulas of 5-aminosalycilic acid drugs in ulcerative colitis were prescribed in about 50% of cases (it was significantly less than commonly used in Crohn’s disease). Corticosteroids were used in the treatment of 16.6% of ulcerative colitis patients and in 24.4% Crohn’s disease patients. In both diseases in the conditions of inpatient treatment, this group of drugs was used several times more often than in outpatient observation. Immunosuppressants (tyopurines, methotrexate) were administered in 6.9% ulcerative colitis patients with and in 17.0% Crohn’s disease patients.Conclusion. Clinical features of inflammatory bowel diseases in St. Petersburg and the features of basic therapy in comparison with the nationwide indicators in Russia demonstrate similar trends. The key problem points of therapy of inflammatory bowel diseases remains the widespread use of drugs of the group of 5-aminosalycilic acid in Crohn’s disease, insufficient use of rectal forms of 5-aminosalycilic acid in ulcerative colitis, a relatively small frequency of use of immunosupressors to maintain remission in Crohn’s disease. The solution to the problem of optimizing the therapy of patients with inflammatory bowel diseases within the framework of routine practice includes educational activities, as well as the creation of a regional register of patients with inflammatory bowel diseases in St. Petersburg.

17 January 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
YUYu. P. Uspenskiy
Yu. P. Uspenskiy
SISergei Vitalyevich Ivanov
Sergei Vitalyevich Ivanov
YFYu. A. Fominykh
Yu. A. Fominykh
ANA. N. Narkevich
A. N. Narkevich
ASA. M. Segal’
A. M. Segal’
ЮФЮ. А. Фоминых
Ю. А. Фоминых
Introduction. Inflammatory Bowel Disease (IBD) including Crohn’s Disease (CD) and Ulcerative Colitis (UC) representsis a challenge for gastroenterologists worldwide, due to its potential to cause life-threatening complications and lead to disability in patients. Aim: to develop a tool that can be used in clinical practice to predict the development of life-threatening complications of IBD through mathematical modeling. Methods. A historical cohort of 291 adult patients with a verified diagnosis of IBD (48% - CD, 52% - UC) who sought medical care from 2020 to 2022 comprised the study base. The outcomes were life-threatening complications including a subgroup of conditions that required urgent surgical intervention. Logistic regression, classification trees and neural network analysis were used to predict the studied outcomes. Results. Life-threatening complications occurred in 22.3% of CD- and in 9.9% of UC patients. The corresponding numbers for urgent surgical complications were 16.5% and 1.3%. Among the constructed mathematical models for both types of outcomes, neural network models demonstrated the highest sensitivity and specificity. Based on the neural network models, two software products named “IBD prognosis: risk of life-threatening complications” and “ IBD prognosis: risk of urgent surgical complications” were developed. For the former, the positive predictive value was 65.0% (95% CI 52.4-75.8) while the negative predictive value was 97.0% (95% CI: 93.9-98.5). For the latter, the corresponding numbers were 77.4% (95% CI: 60.2-87.4) and 99.2% (95% CI: 97.2-99.8). Conclusions. Two tools have been developed for use in clinical practice by gastroenterologists, therapists, and general practitioners to manage IBD patients. Identifying a high-risk IBD patient for developing a life-threatening complication can be used as a foundation for optimizing the therapy used in the treatment of a given patient, potentially saving lives.

31 May 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
NBNataia V Baryshnikova
Nataia V Baryshnikova
YUY P Uspenskiy
Y P Uspenskiy
YFY A Fominykh
Y A Fominykh
SPS V Petlenko
S V Petlenko
VZV A Zaplutanov
V A Zaplutanov
AKA A Krasnov
A A Krasnov
Aim. To analyze the anti-inflammatory efficacy of Regasthym Gastro (alpha-glutamyl-tryptophan) in the treatment of patients with chronic atrophic gastritis according to endoscopic and morphometric studies. Materials and methods. As part of a double-blind placebo-controlled study, the results of gastroscopy and histological (morphometric) studies were retrospective analyzed in 80 patients diagnosed with chronic atrophic gastritis associated with Helicobacter pylori in exacerbation: 43 patients took Regasthym Gastro, 37 patients placebo. The conclusions of the gastroscopy were structured in the form of a standardized scale, which included an assessment of criteria in points (from 0 to 3): thickness of folds, hyperemia, edema of the gastric mucosa, the signs of atrophy, metaplasia; the severity of the erosive process. The sum of points according to all criteria was used to assess the dynamics of the inflammatory process: positive dynamics; lack of dynamics; the pathological process is progressing. The results of the endoscopic examination were compared with morphometry data (the number of inflammation pool cells per 1 mm2 of gastric mucosa). Statistical processing of the results was carried out using the Statistica 12 application software package. Results. According to the gastroscopy, before therapy, hyperemia of the gastric mucosa was present in 82.5%, edema in 53.8%, erosion in 17.5%, signs of metaplasia in 12.5% of patients. After therapy with the investigated drug a statistically significant decrease in the severity of edema of the gastric mucosa (p=0.008), the total set of signs of acute inflammatory process (p=0.006), a decrease in the proportion of outcomes with negative dynamics of the inflammatory process (p=0.038) was revealed. Statistically significant (p0.05) correlations were found between gastroscopy data of inflammation and the number of neutrophil, eosinophil granulocytes, macrophages and lymphocytes per 1 mm2. Conclusion. Regasthym Gastro contributes to a significant decrease in the severity of the inflammatory process according to the evaluation of the results of gastroscopy and morphometry. It is possible to recommend the inclusion of this drug in the complex therapy of chronic gastritis to increase the effectiveness and reduce the risks of progression of inflammation.

7 July 2020 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
YUY. P. Uspenskiy
Y. P. Uspenskiy
YFY. A. Fominykh
Y. A. Fominykh
KNK. N. Nadzhafova
K. N. Nadzhafova
SPS. V. Polyushkin
S. V. Polyushkin
ЮУЮ. П. Успенский
Ю. П. Успенский
ЮФЮ. А. Фоминых
Ю. А. Фоминых
Aim of review. The review highlights modern concepts of the role of microbiome in sustaining the human body, the place of probiotics in treatment and prevention of pathologies related to disorders in healthy microbiota.Key points. Microbiome is a unique panorganismal system normally maintaining self-equilibrium and possessing a vast and diverse functionality. Imbalance in normal microbiota can be assisted by probiotics, i.e. living microorganisms that sustain health of the host when being supplied in adequate amounts. Alike normal microflora, probiotic strains incorporate into general metabolism by mediating a spectrum of functions, e.g. maintaining colonisation resistance, nutrient metabolism, supplying the host with vital metabolites, regulation of local and adaptive immune responses, enhancing the intestinal barrier. Probiotics are applied in various diseases associated with general imbalances of the organism. Modern probiotic preparations are characterised by acid- and antibiotic-resistivity and safety, thus being suitable for treating gut microbiome-associated disorders in various age groups.Conclusion. Probiotic strains, as well as medications designed on their basis, are widely applied and show good promise. Further research into their properties will advance the prospects of probiotic treatment.